Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Urogen Pharma (URGN) had Normalized Pre-Tax Income of $-98.32M for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
$82.71M |
|
$-102.24M |
|
$9.36M |
|
$73.35M |
|
$148.25M |
|
$-65.54M |
|
$-32.79M |
|
$-98.32M |
|
|
Normalized Pre-Tax Income |
$-98.32M |
$-102.24M |
|
$-102.24M |
|
$-102.24M |
|
$-102.24M |
|
$-65.54M |
|
$-65.77M |
|
28.83M |
|
28.83M |
|
$-3.55 |
|
$-3.55 |
|
| Balance Sheet Financials | |
$169.19M |
|
$0.69M |
|
$9.12M |
|
$178.31M |
|
$31.21M |
|
$98.55M |
|
$212.31M |
|
$243.52M |
|
$-65.21M |
|
$-65.21M |
|
$-65.21M |
|
32.49M |
|
| Cash Flow Statement Financials | |
$-76.38M |
|
$-0.95M |
|
$116.93M |
|
$56.22M |
|
$95.82M |
|
$39.60M |
|
$9.34M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.42 |
|
-- |
|
-- |
|
2.96 |
|
-1.51 |
|
88.68% |
|
-79.23% |
|
-79.23% |
|
-79.51% |
|
-118.87% |
|
-123.61% |
|
$-76.57M |
|
-- |
|
-- |
|
-- |
|
0.46 |
|
1.65 |
|
5.36 |
|
68.15 |
|
156.79% |
|
156.79% |
|
-57.34% |
|
-306.68% |
|
$-2.01 |
|
$-2.66 |
|
$-2.65 |
|